EU · Phase II & III · Plaque psoriasis
EU plaque psoriasis Phase II & III trials: sites, investigators, CROs and recruitment competition
Thirty-eight EU Phase II and III studies have targeted patients with plaque psoriasis. The network spans 505 distinct listed sites and 557 investigators, with Poland, Germany and Spain carrying the deepest repeated trial experience.
Top 5 sites
University of Debrecen leads with 14 plaque psoriasis trials
Hospital de la Santa Creu i Sant Pau follows with 13. Three Polish research centres each contributed to at least 12 studies.
Repeated participation indicates relevant plaque psoriasis trial experience, not current capacity or recruitment performance.
Top 5 investigators
Andrea Szegedi leads investigator experience with 13 trials
Wojciech Baran and Andrzej Kaszuba each contributed to 12 studies. Nina Magnolo and Athanasios Tsianakas follow with 10 each.
Country footprint
Poland appears in 32 of the 38 studies
Germany follows with 27 studies and Spain with 22. Poland also has the widest site network, with 153 distinct listed centres.
CRO comparison
PPD has the broadest documented operational experience across eight trials
Fortrea supports three studies. ARENSIA, ICON and Parexel each contribute to two, based on disclosed monitoring, project management, regulatory, recruitment, data or safety responsibilities.
CRO recurrence shows documented experience in this trial set, not CRO quality or performance.
Current recruitment competition
Nine plaque psoriasis trials are still recruiting in at least one EU country
Poland currently carries five recruiting programs. Germany and France each carry four, while Spain carries three.
Recruitment overlap
Poland, Germany and SpainDeepest repeated trial experienceThe countries with the largest historical plaque psoriasis networks also carry several active recruiting studies. Site-level overlap is therefore particularly relevant when planning another late-stage program.
Recruiting status is country-level. It does not establish that every listed site in that country is currently open.
Source: EU CTIS trial entries, country recruitment status, sites, investigators and disclosed third-party organizations, reviewed 21 September 2026. Scope includes 38 distinct Phase II, IIb, III and IIIb studies whose target population is plaque psoriasis, including studies recorded under broader psoriasis labels where eligibility confirms plaque psoriasis.